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1. Introduction 
Mesenchymal stem cells (MSCs) are multipotent, adult stem cells that show clinical potential 
as therapeutic agents in regenerative medicine(Bruder et al., 1994; Barry, 2003; Alhadlaq & 
Mao, 2004; Gangji et al., 2005; Cha & Falanga, 2007). They are also known as marrow 
stromal cells and are derived from mesodermal tissues. The clonal nature of a sub-
population of marrow nucleated cells was discovered in the 1960’s (Becker et al., 1963). 
These cells were later assayed and renamed “colony forming fibroblasts”(Friedenstein et al., 
1974). Experiments through the 1980’s and 1990’s demonstrated that environmental clues 
assisted MSCs in differentiating into different cell types. For example, culturing with 
ascorbic acid, inorganic phosphate, or dexamethasone could differentiate cells to osteoblasts, 
while culturing in the presence of TGF-beta caused cells to differentiate into chondrocytes 
(Alhadlaq & Mao, 2004). More recently it has been shown that bone marrow MSCs are 
actually a heterogeneous population of similar cells rather than one distinct cell type (Zhou 
et al., 2005). As a result, there is still no uniformly accepted definition of an MSC. Despite 
this issue, some groups have attempted to provide a definition which consists of adherence 
to plastic, MSC specific cell surface markers consistent with MSCs, as well as multi-lineage 
mesodermal tissue differentiation (Schauwer et al., 2010).  
2. Cell source matters 
MSCs can be easily isolated from many anatomic locations, including whole marrow aspirate, 
marrow mobilized whole blood, muscle biopsy, adipose liposuction aspirate, and other tissues 
(Alhadlaq & Mao, 2004). For orthopedic uses, these sources have been compared by many 
authors for their ability to heal bone and cartilage with differences being uncovered. As a rule, 
the closer the source tissue is to the target tissue being treated, the more effective the MSCs 
appear to be at differentiation to the target tissue type. For example, Vidal compared equine 
MSCs derived from bone marrow (bm-MSCs) vs. adipose tissue (a-MSCs) for chondrogenic 
potential and found that bm-MSCs produced a more hyaline like matrix and had improved 
glycosaminoglycan production (Vidal et al., 2008). Additional animal studies demonstrated 
that bm-MSCs produced better repair of a tibial osteochondral defect when compared to a-
MSCs (Niemeyer et al., 2010). Keeping with this trend, Yoshimura determined that MSCs 
derived from the synovial tissue of the knee (closest to the target tissue of chondral cartilage) 
had better chondrogenesis than bm-MSCs (Yoshimura et al., 2007).  
Significant controversy exists over whether adipose or bone marrow are better sources for 
orthopedic tissue repair (Frisbie et al., 2009). While adipose MSCs are more prevalent and 
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are capable of orthopedic tissue differentiation, obtaining orthopedic tissues from these type 
of cells requires the use of considerably more growth factors. In addition, as stated above, 
the native chondrogenic potential of adipose derived MSCs doesn’t appear to be as robust as 
bone marrow derived MSCs.  
3. MSC culture expansion  
A limited amount of cells can be obtained from any tissue. In many instances, the number 
that can be harvested from the source tissue is less than the quantity of cells needed for 
tissue repair. One method of obtaining more cells is culturing to obtain larger numbers. 
However, a delicate balance exists between length of time in culture (which produces more 
cells) and adverse consequences to the cells (such as genetic transformation).  
MSCs are usually culture expanded via monolayer culture, which is a process that involves 
seeding a certain density of cells onto a specialized flask and allowing the MSCs to attach to 
a plastic surface and begin to form colonies. In this way, MSCs are selected from the marrow 
nucleated cell population through adherence. The MSC’s that are adherent are then fed via a 
nutrient broth that is maintained above the growing cells. Oftentimes flasks are used with 
multiple surfaces to enhance cell production versus available incubator space. Because 
MSCs are contact inhibited, they will grow on this surface until they become confluent and 
then abruptly stop propagating. It is commonly believed that this “contact inhibition” 
property of MSCs is a key feature of their enhanced safety profile over other stem cell types 
that will propagate indefinitely without exhibiting contact inhibition. To keep MSCs 
proliferating in culture, when the colonies are near confluence, the non-adherent cells in the 
media are discarded and an enzyme is used to detach the MSCs from the plastic surface. The 
MSCs are then re-plated in a similar flask and fresh media added with this process being 
known as a “passage”. Most MSCs in culture are grown to the 2nd to 5th passage, as some 
studies have shown decreased differentiation if MSCs are grown for prolonged periods in 
culture with a higher chance of genetic mutation (see Fig. 1)(Banfi et al., 2000; Crisostomo et 
al., 2006; Izadpanah et al., 2008). Thus MSC culture is a balance between being able to grow 
additional cells for therapy without culturing for prolonged periods. Most studies consider 
that a “pure” MSC population is obtained after approximately the second passage.  
 
 
Fig. 1. Adverse changes in cells increase with time in culture as biologic potency decreases. 
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4. How MSC’s effect tissue repair  
Animal studies have demonstrated the multipotency of MSCs, and how they can 
differentiate into muscle, bone, cartilage, tendon, and various cells of internal organs. 
However, these cells also act via paracrine mechanisms to assist in tissue repair. For cell 
therapy, paracrine is defined as the production of certain growth factors and cytokines by 
the MSCs which can assist in tissue repair (Ladage et al., 2007). These growth factors include 
TGF-beta, VEGF, FGF, and other signaling factors that can help recruit other cells to the local 
area. In this way, MSCs can act as a coordinator of the repair response without having to act 
directly through differentiation to repair tissue. In fact, some have questioned whether most 
of the positive repair effects observed in experimental MSC therapies are due more to this 
paracrine signaling than differentiation of cells. In the end, it may not matter if MSCs act 
through differentiation or orchestrate the repair response, as long as the robustness of the 
repair meets the clinical need.  
5. Donor vs. autologous MSC sourcing 
Autologous stem cells obviously do not have the same communicable disease transmission 
risk as donor allogeneic cells. However, there may be practical reasons why donor cells are 
attractive. For example, some studies have shown a decreased differentiation potential for 
MSCs obtained from older patients (Zhou et al., 2008). In addition, somatic genetic variants 
(i.e. trisomy V and VII) have been demonstrated in the MSCs and osteoprogenitors of some 
patients with osteoarthritis (Broberg et al., 1998). In addition, allogeneic cells could be able 
to be mass produced in bioreactors, providing a ready supply of cells for therapy. On the 
other hand, some concerns have been raised about the use of allogeneic stem cells. As an 
example, Ueda recently discovered that stem cells transplanted from the bone marrow of 
elderly mice bred to have osteoporosis were able to induce osteoporosis in young healthy 
mice, indicating that the stem cells themselves may be a genetic disease vector (Ueda et al., 
2007). In addition, many have argued that allogeneic MSCs are immune-privileged as they 
lack major histocompatibility complexes; however, Prigozhina has found that allogeneic 
MSCs lose their immunosuppressive potential in a mismatched setting (Prigozhina et al., 
2008). In addition, Huang recently noted that MSCs transplanted for cardiac repair lost their 
immune-privileged status and transitioned to an immunogenic state after differentiation, 
limiting their usefulness in cardiac repair (Huang et al., 2010). In summary, while allogeneic 
MSCs may solve some issues such as cell availability on demand and mass distribution, they 
also present many hurdles that have to be overcome to allow lab to bedside translation.  
6. MSC use in orthopedic specific conditions 
6.1 Fibrocartilage-meniscus repair 
The challenge in repairing the meniscus is due to the poor blood supply of the inner 2/3’rds 
(where many tears occur) versus the good blood supply of the outer 1/3 (red zone-where 
fewer non-healing tears are observed) (Hennerbichler et al., 2007). As a result of these 
differences in meniscus blood and nutrient supply, surgical repair of a meniscus tear is more 
likely to be successful in the outer 1/3 than the inner 2/3rd’s. To overcome this limited 
healing ability of the inner 1/3rd of the meniscus, many surgeons often perform a partial 
mensectomy for tears of this area, which can lead to significant biomechanical abnormalities 
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in the knee (Sturnieks et al., 2010). The promise of stem cells if used to enhance surgery may 
thus be in allowing the surgeon to repair the inner meniscus. For example, Izuta et al 
demonstrated that cultured MSCs may be able to overcome this problem of poor repair in 
the avascular zone. His group was able to demonstrate meniscus repair in the white zone 
when MSCs were transplanted into this area using a fibrin matrix (Izuta et al., 2005). Of 
note, Agung et al (2006) reported a murine model of intra-articular injection after acute 
injury of multiple knee structures, including the meniscus. This model demonstrated that 
for blind intra-articular injection (rather than the local adherent model proposed by Koga), 
the number of cells injected was related to their ability to be found in the meniscus. For 
example, at a dose of 1 X 106 MSCs, none were found in the injured meniscus but at a dose 
of 1 X 107 cells, MSCs were generally found in this area. This may fit well with Koga’s 
hypothesis that MSCs act primarily where they physically attach, as a higher number of cells 
injected into the joint would make it more likely that cells would be able to attach at the site 
in need of repair (Koga et al., 2008). Horie et al (2009) reported that synovial derived MSCs 
that were injected into massive rat meniscus tears were able to differentiate and repair 
meniscal tissue. Of note, the authors also demonstrated that these cells did not migrate out 
of the knee to distant organs, further enhancing their theoretical safety profile for clinical 
use. Finally, Yamasaki et al (2005) validated that MSCs were capable of repopulating the 
meniscus. This investigator cryogenically treated the meniscus to kill the living cells and 
then reseeded it with cultured MSCs. The resulting tissue had appropriate biomechanical 
properties approximating the normal meniscus.  
6.2 Hyaline cartilage: chondral defects 
Some of the earliest models of cartilage repair used autologous, cultured chondrocytes 
(Brittberg et al., 1994). However, the complications of using chondrocytes for cartilage repair 
included hypertrophy, graft failure, long culture times, and the invasiveness of the implant 
procedure (Nejadnik et al., 2010). Because MSC’s are multi-potent and have shown to have 
innate cartilage repair properties through both differentiation and paracrine signaling, 
animal models of cartilage repair using MSCs started to appear in the literature in the early 
1990’s (Caplan, 1991). In these studies an osteochondral defect (OCD) was created 
experimentally and the MSCs were implanted into the lesion, often in a hydrogel or other 
carrier or at times through local adherence (Minas & Nehrer, 1997; Buckwalter & Mankin, 
1998; Angele et al., 1999; Johnstone & Yoo, 1999). Partial to robust healing of the OCD takes 
place over weeks to months (Alhadlaq & Mao, 2004). The cartilage produced by these cells 
was very much like native hyaline cartilage, but subtle differences have been observed 
(Katakai et al., 2009). 
6.3 Biologic scaffolding 
MSCs can be delivered to the lesion area in many different biologic scaffolds including 
hydrogels, fibrin, in native extra-cellular matrix, collagen, or in a suspension. A scaffold is 
a matrix with properties that support cell migration, attachment, three dimensional 
position, and engraftment. Based on unpublished data, we have noted that stiffer biologic 
scaffolds (like dense fibrin glue) tend to reduce MSC viability as they limit MSC 
movement through the material. On the other end of the spectrum is implanting MSCs 
without scaffolding. In this method, cells are delivered in a liquid suspension and slowly 
dripped on the lesion, using gravity dependent adherence to allow site attachment. For 
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example, Fig 2 shows histology adapted from Koga et al (2008) demonstrating minimal 
cartilage repair with a control saline injection, minimal repair with MSC’s injected  
intra-articular, and robust repair when MSCs were allowed to attach to the lesion via 
gravity.  
Based on the published data showing the importance of MSC attachment to a lesion, we 
would hypothesize that exact placement of MSCs in a joint is very important. For example, 
blind intra-articular injection of MSCs or the placement of cells into the intra-articular cavity 
after surgery is likely to be less effective for facilitating repair than placement of cells at or 
near a lesion in need of repair. This exact placement of cells has been already used in daily 
orthopedics practice, for example in the Autologous Chondrocyte Implantation procedure 
(ACI) as well as in knee micro fracture. The knee ACI procedure depends on exact 
placement of cultured chondrocytes into an osteochondral defect through injection under a 
surgically prepared periosteal flap. The micro fracture procedure also relies on the surgeon 
creating holes in the osteochondral plate of an OCD (Osteochondral Defect) which allows 
whole marrow and a limited number of MSCs to clot in the defect.  
 
 
Fig. 2. Histology of chondral cartilage repair after staining, showing little repair in a control 
injection, some repair in a blind intra-articular injection of stem cells, and robust repair 
when cells were dripped on the lesion. 
While existing cell based procedures for the knee have some reported success, both of 
these techniques seem to be more effective in younger, athletic patients. In addition, in 
both procedures, the cartilage produced by either chondrocytes or the low concentration 
of MSCs in a micro fracture clot tends more toward non-native fibrous cartilage versus the 
more hyaline like cartilage produced by higher concentrations of cultured MSCs 
(Mobasheri et al., 2009). Recently, McIlwraith et al have improved upon the standard 
micro fracture concept in an equine model by adding MSC’s to the joint after surgery, 
demonstrating better cartilage repair with a combination of micro fracture plus MSCs 
than microfracture alone (McIlwraith, 2010). In this study, the repaired tissue was 
significantly firmer and had higher levels of aggrecan, a molecule that provides 
compressive stiffness to cartilage. 
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6.4 Tendon repair 
Tendon tears are often difficult to treat without a high level of morbidity or re-rupture. 
This may be because of the high tensile strength tendons are required to bear as well as 
the fact that sutures in the tendon itself may reduce local blood flow, further impeding the 
repair process. Awad has published a rabbit model demonstrating that cultured MSCs 
were able to assist healing and produced better tendon appearance than non-MSC treated 
tendons. The MSC treated tendons had better maximum stress, modulus, and strain 
energy density as well as minor improvements in the histological appearance, including 
an increased number of tenocytes and larger and more mature-looking collagen fiber 
bundles (Awad et al., 1999). The same author later published that the seeding density of 
MSCs in the biologic scaffold and control over the rate of contraction of the healing 
tendon were important for successful MSC mediated tendon repair (Awad et al., 2000). 
Chong also demonstrated improved modulus in resected rabbit Achilles tendons treated 
with MSCs and morphometric changes, concluding that MSCs can improve the 
histological and biomechanical parameters in the early stages of tendon-healing (Chong et 
al., 2007). On the other hand, Gulotta was unable to demonstrate efficacy for an animal 
model of surgical rotator cuff tendon healing which showed no differences between MSC 
treated and untreated groups (Gulotta et al., 2009).  
6.5 Intervertebral disc repair 
Traditional spinal surgery treatments for degenerated intervertebral discs continue to show 
disappointing results (Deyo et al., 1993; Elias et al., 2000; Fritzell et al., 2003). While animal 
models of disc repair using MSCs are abundant, human data isn’t readily available. For 
example, Sakai et al (2003, 2006) have published several animal models whereby MSCs are 
usually combined with atellocollagen and inserted into an experimentally created 
degenerative disc. This group of authors has observed encouraging improvements in MRI 
disc hydration, height, and morphology. Richardson et al (2004) and Risbud et al (2004) 
have investigated the co-culturing of MSCs with cells from the nucleus pulposis (NP) 
showing that this technique can produce partially differentiated cells that are capable of 
repopulating the NP in an animal model. Risbud et al (2004) has also used different methods 
for MSC differentiation toward the NP phonotype including using MSC exposure to 
hypoxia and TGF-beta in culture. Zhang et al (2005) has shown that MSCs injected into discs 
without pre-conditioning or co-culture can help to increase proteoglycan production in the 
NP. Finally, Miyamota et al (2010) recently demonstrated that intra-discal transplantation of 
synovial derived MSCs prevented disc degeneration through suppression of catabolic genes 
and perhaps proteoglycan production. In summary, while the results from animal models 
are impressive, questions remain as to whether a quadruped disc with its very different load 
characteristics can serve as an adequate model for bipedal disc repair. In addition, in all of 
the animal models studied to date, an artificially created degenerated disc (acute disc stab 
model) is used as a surrogate for the chronic degenerated discs normally encountered in 
patients (Yoshikawa et al., 2010). 
7. Cell delivery in orthopedics 
Delivery of cells into a joint to treat orthopedic injuries could take two common routes used 
daily in clinical practice: percutaneous injections and arthroscopic placement.  Injecting cells 
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into a confined space such as infiltrating into soft-tissues will likely result in the MSC’s that 
stay local to the injection site. However, as discussed above, injecting in a large joint 
presents some concerns, as multiple animal models have shown that cells may or may not 
find their way into the damaged areas(Agung et al., 2006). Because MSC’s function through 
local attachment to the damaged site, MSCs dripped on a lesion surgically or through a 
needle are another possible implant route. Other injection based methods may involve using 
MSCs tagged with ferrous nanoparticles and magnetic fields to encourage attachment to the 
damaged site (Kobayashi et al., 2008). Finally, since MSCs are capable of chemotaxis, placing 
certain growth factors on the injured tissue may result in more MSCs accumulating at the 
lesion (Fiedler et al., 2002).  
Another challenge in MSC delivery is that most arthroscopic surgery is performed in a 
water environment. For cells in suspension, this presents a challenge, as the MSCs would 
easily be whisked away by the action of arthroscopy pumps meant clear debris from the 
operative site. To overcome this problem, Nejadnik et al (2010) have used a surgical 
approach similar to autologous chondrocyte implantation, where MSCs are placed in a 
dense hydrogel and sutured under a protective membrane. While this technique has 
promise, it’s also more surgically invasive with likely higher morbidity than injection. 
Another alternative method is to adapt the MSC properties to be better suited for the water 
arthroscopy environment. For example, MSCs can be cultured to form a tissue engineered 
construct (TEC) by allowing the cells to produce their own extracellular matrix. The result is 
a pea sized implant with a paste like consistency that can be placed under water arthroscopy 
into a lesion or defect (Ando et al., 2007).  
8. From the bench to the bedside in orthopedics 
The clinical translation of MSCs from the lab to the bedside is clearly imminent. For 
example, our use of MSCs in orthopedics began in 2005 and we have published case studies 
in which positive MRI changes in cartilage and meniscus were observed in knees treated 
with culture expanded MSCs and hips treated with nucleated cell concentrates, 
corresponding with symptomatic improvement (Centeno et al., 2006; Centeno et al., 2008; 
Centeno et al., 2008). We have also noted that the complication rate of expanded MSC 
injection procedures is no greater than other needle-based interventional techniques 
directed at peripheral joints (Centeno et al., 2010). In a submitted and recently accepted 
publication on 339 patients, this safety profile was continued at up to three years post MSC 
reimplantation with over 200 MRI’s of the reimplant sites showing no evidence of ectopic 
tissue or tumor formation (see Fig 3). Other authors have described similar safety profiles 
using more invasive surgical implant techniques. Wakatani described effective treatment of 
cartilage defects in 9 knees with culture expanded MSCs (Wakitani et al., 2007). These 
authors also published an 11-year prospective study of 45 knees (in 41 patients) treated with 
autologous cultured, bone marrow MSCs, with results indicating both safety and efficacy 
(Wakitani et al., 2010). Nejadnik recently described a comparison between surgically 
implanted chondrocytes versus cultured MSCs placed by needle in 72 knees of older 
patients.(Nejadnik et al., 2010) The MSC treated knees demonstrated good safety, less donor 
site morbidity, and better efficacy when compared with an autologous chondrocyte 
implantation procedure. Finally, Haleem has noted that autologous, cultured bm-MSCs re-
implanted into articular cartilage defects in platelet rich fibrin demonstrated evidence of 
healed cartilage in most patients at 12 months post-operative.(Haleem et al., 2010) 
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Fig. 3. Number of negative MRI follow-ups at re-implant sites for each end-point for 50 
patients tracked after orthopedic MSC reimplantation. 
While very little has been published on intervertebral disc repair in humans, some clinical 
data is available. Yoshikawa recently published on two patients who were treated with 
surgically implanted MSCs that were cultured using a serum free technique (Yoshikawa et 
al., 2010). After two years, no complications were noted and both patients showed modest 
improvements in vacuum phenomena on follow-up MRI. The only other human data of 
which we are aware is that produced by our group from 2005-2010 under IRB supervision 
and now being readied for publication (unpublished data). Our experience demonstrated 
that placing a bone marrow nucleated cell fraction (an enriched MSC population with other 
cells) into the disc via percutaneous means produced no measureable clinical or MRI results 
in patients with degenerative disc disease. Replicating the Sakai study (Sakai et al., 2003), 
where cultured MSCs were placed into the disc in a similar patient population also 
produced little measureable results. Finally, a third case series was performed where 
changes were made in culture and injection technique as well as the diagnosis being treated 
(changed from DDD to chronic disc bulge causing lumbar radiculopathy). This last model 
showed encouraging clinical and imaging results. 
9. Implications in real world clinical applications  
To consider the real world implications of viable cell based alternatives to more invasive 
orthopedic surgeries, total knee arthroplasty (TKA) is an apt model.  Knee replacement 
surgery, also called knee arthroplasty, has been employed increasingly over the past 10 
years as a means of treating symptomatic degenerative changes of the knee. It is estimated 
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from discharge data from the Nationwide Inpatient Sample (NIS) of the Healthcare Cost and 
Utilization Project (HCUP), that the number of partial and total knee replacement 
procedures among U.S. patients 65 years and older increased dramatically from 178,653 in 
2000 to 357,472 in 2008 (HCUP, 2008). Knee arthroplasty is associated with substantial 
mortality and morbidity; applying rates derived from 2000 data resulted in an estimated 
4,964 TKA related deaths, 2,788 pulmonary emboli, 2,908 myocardial infarcts, and 4,670 
cases of pneumonia (Mahomed NN, 2005). In contrast, we have recently submitted for 
publication a large case series of 202 knee and hip osteoarthritis patients treated with 
percutaneous injection of MSC’s. As an example, while 2/3’rds of the knee patients were 
TKA candidates, only 6 knee patients reported TKA within an average total surveillance 
period of >2 years despite the injection. In addition, statistically significant differences in 
reported outcome between the treatment and an untreated control were observed. Finally, 
complications rates were minimal compared to TKA.  
10. Regulatory processes 
The regulatory environment in the United States and Europe for stem cells that are more 
than minimally manipulated considers these cells in the same regulatory category as mass 
produced drugs. This “drug” category includes cultured cells, using any cell for a non-
homologous use (for example an adipose MSC for an orthopedic indication), and cells that 
have significant processing beyond a simple centrifugation. This regulatory posture has led 
to a prolonged approval process to bring these technologies from the bench to the bedside. 
While this approach may certainly make sense for mass produced cells being distributed en 
masse in vials, this same approach is also applied to autologous cells where the lot size is 
one patient. As a result, real world clinical knowledge on the clinical use of stem cells in 
patients is largely accumulating outside the U.S. and Europe. Many stem cell clinics have 
proliferated worldwide in countries with less stringent regulatory structures. 
11. References 
Agung, M., Ochi, M., Yanada, S., Adachi, N., Izuta, Y., Yamasaki, T. & Toda, K. (2006). 
Mobilization of bone marrow-derived mesenchymal stem cells into the injured 
tissues after intraarticular injection and their contribution to tissue regeneration. 
Knee Surg Sports Traumatol Arthrosc, Vol. 14, No. 12, pp. 1307-1314, ISSN 0942-2056. 
Alhadlaq, A. & Mao, J.J. (2004). Mesenchymal stem cells: isolation and therapeutics. Stem 
Cells Dev, Vol. 13, No. 4, pp. 436-448. 
Ando, W., Tateishi, K., Hart, D.A., Katakai, D., Tanaka, Y., Nakata, K., Hashimoto, J., Fujie, 
H., Shino, K., Yoshikawa, H. & Nakamura, N. (2007). Cartilage repair using an in 
vitro generated scaffold-free tissue-engineered construct derived from porcine 
synovial mesenchymal stem cells. Biomaterials, Vol. 28, No. 36, pp. 5462-5470, ISSN 
0142-9612. 
Angele, P., Kujat, R., Nerlich, M., Yoo, J., Goldberg, V. & Johnstone, B.  (1999). Engineering 
of osteochondral tissue with bone marrow mesenchymal progenitor cells in a 
derivatized hyaluronan-gelatin composite sponge. Tissue Eng, Vol. 5, No. 6, pp. 545-
554, ISSN 1076-3279. 
www.intechopen.com
 
Advances in Regenerative Medicine 
 
358 
Awad, H.A., Butler, D.L., Boivin, G.P., Smith, F.N., Malaviya, P., Huibregtse, B. & Caplan, 
A.I. (1999). Autologous mesenchymal stem cell-mediated repair of tendon. Tissue 
Eng, Vol. 5, No. 3, pp. 267-277. 
Awad, H.A., Butler, D.L., Harris, M.T., Ibrahim, R.E., Wu, Y., Young, R.G., Kadiyala, S. & 
Boivin, G.P. (2000). In vitro characterization of mesenchymal stem cell-seeded 
collagen scaffolds for tendon repair: effects of initial seeding density on contraction 
kinetics. J Biomed Mater Res, Vol. 51, No. 2, pp. 233-240, ISSN 1097-4636. 
Banfi, A., Muraglia, A., Dozin, B., Mastrogiacomo, M., Cancedda, R. &  Quarto, R. (2000). 
Proliferation kinetics and differentiation potential of ex vivo expanded human bone 
marrow stromal cells: Implications for their use in cell therapy. Exp Hematol, Vol. 
28, No. 6, pp. 707-715, ISSN 0301-472X. 
Barry, F.P. (2003). Mesenchymal stem cell therapy in joint disease. Novartis Found Symp, Vol. 
249, No. 86-96; discussion 96-102, pp. 170-104, 239-141. 
Becker, A.J., Mc, C.E. & Till, J.E. (1963). Cytological demonstration of the clonal nature of 
spleen colonies derived from transplanted mouse marrow cells. Nature, Vol. 197, 
pp. 452-454, ISSN 0028-0836. 
Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O. & Peterson, L. (1994). 
Treatment of deep cartilage defects in the knee with  autologous chondrocyte 
transplantation. N Engl J Med, Vol. 331, No. 14, pp. 889-895, ISSN 0028-4793. 
Broberg, K., Hoglund, M., Lindstrand, A., Toksvig-Larsen, S., Mandahl, N. & Mertens, F. 
(1998). Polyclonal expansion of cells with trisomy 7 in synovia from patients with 
osteoarthritis. Cytogenet Cell Genet,  Vol. 83, No. 1-2, pp. 30-34, ISSN 0301-0171. 
Bruder, S.P., Fink, D.J. & Caplan, A.I. (1994). Mesenchymal stem cells in bone development, 
bone repair, and skeletal regeneration therapy. J Cell Biochem, Vol. 56, No. 3, pp. 
283-294. 
Buckwalter, J.A. & Mankin, H.J. (1998). Articular cartilage: degeneration and osteoarthritis, 
repair, regeneration, and transplantation. Instr Course Lect, Vol. 47, pp. 487-504. 
Caplan, A.I. (1991). Mesenchymal stem cells. J Orthop Res, Vol. 9, No. 5, pp. 641-650, ISSN 
1554-527X. 
Centeno, C.J., Busse, D., Kisiday, J., Keohan, C., Freeman, M. & Karli, D. (2008). Increased 
knee cartilage volume in degenerative joint  disease using percutaneously 
implanted, autologous mesenchymal stem cells. Pain Physician, Vol. 11, No. 3, pp. 
343-353, ISSN 1533-3159. 
Centeno, C.J., Busse, D., Kisiday, J., Keohan, C., Freeman, M. & Karli, D. (2008). 
Regeneration of meniscus cartilage in a knee treated with percutaneously 
implanted autologous mesenchymal stem cells. Med Hypotheses, Vol. 71, No. 6, pp. 
900-908, ISSN 0306-9877. 
Centeno, C.J., Kisiday, J., Freeman, M. & Schultz, J.R. (2006). Partial regeneration of the 
human hip via autologous bone marrow nucleated cell transfer: A case study. Pain 
Physician, Vol. 9, No. 3, pp. 253-256, ISSN 1533-3159. 
Centeno, C.J., Schultz, J.R., Cheever, M., Robinson, B., Freeman, M. &  Marasco, W. (2010). 
Safety and complications reporting on the re-implantation of culture-expanded 
mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell 
Res Ther, Vol. No. 5, pp. 81-93, ISSN 1574-888X. 
Cha, J. & Falanga, V. (2007). Stem cells in cutaneous wound healing. Clin Dermatol, Vol. 25, 
No. 1, pp. 73-78, ISSN 0738-081X. 
www.intechopen.com
 
Regenerative Orthopedics 
 
359 
Chong, A.K., Ang, A.D., Goh, J.C., Hui, J.H., Lim, A.Y., Lee, E.H. & Lim, B.H.  (2007). Bone 
marrow-derived mesenchymal stem cells influence  early tendon-healing in a rabbit 
achilles tendon model. J Bone Joint Surg Am, Vol. 89, No. 1, pp. 74-81, ISSN 0021-
9355.  
Crisostomo, P.R., Wang, M., Wairiuko, G.M., Morrell, E.D., Terrell, A.M., Seshadri, P., Nam, 
U.H. & Meldrum, D.R. (2006). High passage number of stem cells adversely affects 
stem cell activation and myocardial protection. Shock, Vol. 26, No. 6, pp. 575-580. 
Deyo, R.A., Ciol, M.A., Cherkin, D.C., Loeser, J.D. & Bigos, S.J. (1993).  Lumbar spinal 
fusion. A cohort study of complications, reoperations, and resource use in the 
Medicare population. Spine, Vol. 18, No. 11, pp. 1463-1470, ISSN 0362-2436. 
Elias, W.J., Simmons, N.E., Kaptain, G.J., Chadduck, J.B. & Whitehill, R. (2000). 
Complications of posterior lumbar interbody fusion when using a titanium 
threaded cage device. J Neurosurg, Vol. 93, No. 1, pp. 45-52. 
Fiedler, J., Roderer, G., Gunther, K.P. & Brenner, R.E. (2002). BMP-2, BMP-4, and PDGF-bb 
stimulate chemotactic migration of primary human mesenchymal progenitor cells. J 
Cell Biochem, Vol. 87, No. 3, pp. 305-312, ISSN 1097-4644.  
Friedenstein, A.J., Deriglasova, U.F., Kulagina, N.N., Panasuk, A.F., Rudakowa, S.F., Luria, 
E.A. & Ruadkow, I.A. (1974). Precursors for  fibroblasts in different populations of 
hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol, 
Vol. 2, No. 2, pp. 83-92, ISSN 0301-472X. 
Frisbie, D.D., Kisiday, J.D., Kawcak, C.E., Werpy, N.M. & McIlwraith, C.W. (2009). 
Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived 
mesenchymal stem cells for treatment of osteoarthritis. J Orthop Res, Vol. 27, No. 
12., pp. 1675-1680, ISSN 1554-527X. 
Fritzell, P., Hagg, O. & Nordwall, A. (2003). Complications in lumbar fusion surgery for 
chronic low back pain: comparison of three surgical  techniques used in a 
prospective randomized study. A report from the Swedish Lumbar Spine Study 
Group. Eur Spine J, Vol. 12, No. 2, pp. 178-189, ISSN 0940-6719. 
Gangji, V., Toungouz, M. & Hauzeur, J.P. (2005). Stem cell therapy for  osteonecrosis of the 
femoral head. Expert Opin Biol Ther, Vol. 5, No. 4, pp. 437-442. 
Gulotta, L.V., Kovacevic, D., Ehteshami, J.R., Dagher, E., Packer, J.D. &  Rodeo, S.A. (2009). 
Application of bone marrow-derived mesenchymal stem cells in a rotator cuff 
repair model. Am J Sports Med, Vol. 37, No. 11, pp. 2126-2133, ISSN 1552-3365.  
Haleem, A.M., Singergy, A.A., Sabry, D., Atta, H.M., Rashed, L.A., Chu, C.R.,  El Shewy, 
M.T., Azzam, A. & Abdel Aziz, M.T. (2010). The Clinical Use of Human Culture-
Expanded Autologous Bone Marrow Mesenchymal Stem Cells Transplanted on 
Platelet-Rich Fibrin Glue in the Treatment of Articular Cartilage Defects: A Pilot 
Study and Preliminary Results. Cartilage, Vol. 1, No. 4, pp. 253-261, ISSN  1947-6043.  
HCUP. A. f. H. R. a. Quality. & 2008). Nationwide Inpatient Sample Issue. 
Hennerbichler, A., Moutos, F.T., Hennerbichler, D., Weinberg, J.B. & Guilak, F. (2007). 
Repair response of the inner and outer regions of the  porcine meniscus in vitro. Am 
J Sports Med, Vol. 35, No. 5, pp. 754- 762, ISSN 0363-5465.  
Huang, X.P., Sun, Z., Miyagi, Y., McDonald Kinkaid, H., Zhang, L., Weisel, R.D. & Li, R.K. 
(2010). Differentiation of allogeneic mesenchymal stem cells induces 
immunogenicity and limits their long-term benefits for myocardial repair. 
Circulation, Vol. 122, No. 23, pp. 2419-2429, ISSN 1524-4539. 
www.intechopen.com
 
Advances in Regenerative Medicine 
 
360 
Izadpanah, R., Kaushal, D., Kriedt, C., Tsien, F., Patel, B., Dufour, J. &  Bunnell, B.A. (2008). 
Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. 
Cancer Res, Vol. 68, No. 11, pp. 4229-4238, ISSN 1538-7445.  
Izuta, Y., Ochi, M., Adachi, N., Deie, M., Yamasaki, T. & Shinomiya, R.  (2005). Meniscal 
repair using bone marrow-derived mesenchymal stem cells: experimental study 
using green fluorescent protein transgenic rats. Knee, Vol. 12, No. 3, pp. 217-223, 
ISSN 0968-0160. 
Johnstone, B. & Yoo, J.U. (1999). Autologous mesenchymal progenitor cells in articular 
cartilage repair. Clin Orthop Relat Res, Vol. 367, S156-162. 
Katakai, D., Imura, M., Ando, W., Tateishi, K., Yoshikawa, H., Nakamura, N. & Fujie, H. 
(2009). Compressive properties of cartilage-like tissues repaired in vivo with 
scaffold-free, tissue engineered constructs. Clin Biomech (Bristol, Avon), Vol. 24, No. 
1, pp. 110-116, ISSN 1879-1271.  
Kobayashi, T., Ochi, M., Yanada, S., Ishikawa, M., Adachi, N., Deie, M. & Arihiro, K. (2008). 
A novel cell delivery system using magnetically labeled mesenchymal stem cells 
and an external magnetic device for clinical cartilage repair. Arthroscopy, Vol. 24, 
No. 1, pp. 69-76, ISSN 1526-3231. 
Koga, H., Shimaya, M., Muneta, T., Nimura, A., Morito, T., Hayashi, M., Suzuki, S., Ju, Y.J., 
Mochizuki, T. & Sekiya, I. (2008). Local adherent technique for transplanting 
mesenchymal stem cells as a potential treatment of cartilage defect. Arthritis Res 
Ther, Vol. 10, No. 4, pp. R84. 
Ladage, D., Brixius, K., Steingen, C., Mehlhorn, U., Schwinger, R.H., Bloch, W. & Schmidt, 
A. (2007). Mesenchymal stem cells induce endothelial activation via paracine 
mechanisms. Endothelium, Vol. 14, No. 2, pp. 53-63. 
Mahomed NN, B.J., Katz JN, Baron JA, Wright J, Losina E (2005). Epidemiology of total knee 
replacement in the United States Medicare population. J Bone Joint Surg Am, Vol. 87, 
No. 6, ISSN 1222-1228. 
McIlwraith, C.W., Frisbie, D.D., Kisiday, J.D., Kawcak, C.E., Werpy, N.M., Rodkey, W.G., & 
Steadman, R.S. (2010) Use of bone marrow-derived culture-expanded mesenchymal 
stem cells to augment healing of chondral defects treated with microfracture In:  
Proceedings of the 56th Annual Convention of the American Association of Equine 
Practitioners, Moyer, W.A. pp. 27-28. Baltimore, Marlyand, USA.  
Minas, T. & Nehrer, S. (1997). Current concepts in the treatment of articular cartilage defects. 
Orthopedics, Vol. 20, No. 6, pp. 525-538, ISSN 0147-7447. 
Mobasheri, A., Csaki, C., Clutterbuck, A.L., Rahmanzadeh, M. & Shakibaei, M. (2009). 
Mesenchymal stem cells in connective tissue engineering and regenerative 
medicine: applications in cartilage  repair and osteoarthritis therapy. Histol 
Histopathol, Vol. 24, No. 3,  pp. 347-366, ISSN 1699-5848. 
Nejadnik, H., Hui, J.H., Choong, E.P., Tai, B.C. & Lee, E.H. (2010). Autologous  Bone 
Marrow-Derived Mesenchymal Stem Cells Versus Autologous  Chondrocyte 
Implantation: An Observational Cohort Study. Am J Sports Med, Vol. 38, No. 6, pp. 
1110-1116, ISSN 1552-3365. 
Niemeyer, P., Fechner, K., Milz, S., Richter, W., Suedkamp, N.P., Mehlhorn, A.T., Pearce, S. 
& Kasten, P. (2010). Comparison of mesenchymal stem cells from bone marrow and 
adipose tissue for bone regeneration in a critical size defect of the sheep tibia and 
www.intechopen.com
 
Regenerative Orthopedics 
 
361 
the influence of platelet-rich plasma. Biomaterials, Vol. 31, No. 13, pp.  3572-3579, 
ISSN 1878-5905. 
Prigozhina, T.B., Khitrin, S., Elkin, G., Eizik, O., Morecki, S. & Slavin, S. (2008). 
Mesenchymal stromal cells lose their immunosuppressive potential  
after allotransplantation. Exp Hematol, Vol 36, No. 10, pp.  1370-1376, ISSN 0301-
472X. 
Sakai, D., Mochida, J., Yamamoto, Y., Nomura, T., Okuma, M., Nishimura, K., Nakai, T., 
Ando, K. & Hotta, T. (2003). Transplantation of mesenchymal stem cells 
embedded in Atelocollagen gel to the  intervertebral disc: a potential therapeutic 
model for disc  degeneration. Biomaterials, Vol. 24, No. 20, pp. 3531-3541, ISSN 
0142-9612. 
Schauwer, C.D., Meyer, E., Walle, G.R. & Soom, A.V. (2010). Markers of stemness in equine 
mesenchymal stem cells: a plea for uniformity. Theriogenology, Vol. 75, No. 8, pp. 
1431-1443, ISSN 0093-691X. 
Sturnieks, D.L., Besier, T.F. & Lloyd, D.G. (2010). Muscle activations to  stabilize the knee 
following arthroscopic partial meniscectomy. Clin Biomech (Bristol, Avon), Vol. 26, 
No. 3. pp. 292-297, ISSN 1879-1271. 
Ueda, Y., Inaba, M., Takada, K., Fukui, J., Sakaguchi, Y., Tsuda, M., Omae, M., Kushida, T., 
Iida, H. & Ikehara, S. (2007). Induction of senile osteoporosis in normal mice by 
intra-bone marrow-bone marrow transplantation from osteoporosis-prone mice. 
Stem Cells, Vol. 25, No. 6, pp. 1356-1363, ISSN 1549-4918.  
Vidal, M.A., Robinson, S.O., Lopez, M.J., Paulsen, D.B., Borkhsenious, O., Johnson, J.R., 
Moore, R.M. & Gimble, J.M. (2008). Comparison of  chondrogenic potential in 
equine mesenchymal stromal cells  derived from adipose tissue and bone marrow. 
Vet Surg, Vol. 37,  No. 8, pp. 713-724, ISSN 1532-950X. 
Wakitani, S., Nawata, M., Tensho, K., Okabe, T., Machida, H. & Ohgushi, H. (2007). Repair 
of articular cartilage defects in the patello-femoral joint with autologous bone 
marrow mesenchymal cell transplantation: three case reports involving nine 
defects in five knees. J Tissue Eng Regen Med, Vol. 1, No. 1, pp. 74-79, ISSN 1932- 
7005.  
Wakitani, S., Okabe, T., Horibe, S., Mitsuoka, T., Saito, M., Koyama, T.,  Nawata, M., Tensho, 
K., Kato, H., Uematsu, K., Kuroda, R., Kurosaka, M., Yoshiya, S., Hattori, K. & 
Ohgushi, H. (2010). Safety of autologous bone marrow-derived mesenchymal stem 
cell transplantation for cartilage repair in 41 patients with 45 joints  followed for up 
to 11 years and 5 months. J Tissue Eng Regen Med,  Vol. 5, No. 2, pp. 146-150, ISSN 
1932-7005. 
Yoshikawa, T., Ueda, Y., Miyazaki, K., Koizumi, M. & Takakura, Y. (2010). Disc regeneration 
therapy using marrow mesenchymal cell transplantation: a report of two case 
studies. Spine (Phila Pa 1976), Vol. 35, No. 11, pp. E475-480, ISSN 1528-1159. 
Yoshimura, H., Muneta, T., Nimura, A., Yokoyama, A., Koga, H. & Sekiya, I. (2007). 
Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, 
periosteum, adipose tissue, and muscle. Cell Tissue Res, Vol. 327, No. 3, pp. 449-462, 
ISSN 0302-766X. 
Zhou, S., Greenberger, J.S., Epperly, M.W., Goff, J.P., Adler, C., Leboff, M.S. & Glowacki, J. 
(2008). Age-related intrinsic changes in human bone-marrow-derived mesenchymal 
www.intechopen.com
 
Advances in Regenerative Medicine 
 
362 
stem cells and their differentiation  to osteoblasts. Aging Cell, Vol. 7, No. 3, pp. 335-
343, ISSN 1474-9726. 
Zhou, Z., Jiang, E.L., Wang, M., Liu, Q.G., Zhai, W.J., Huang, Y., Wang, H.H. &  Han, M.Z. 
(2005). [Comparative study on various subpopulations in mesenchymal stem cells 
of adult bone marrow]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, Vol. 13, No. 1, pp. 54-
58, ISSN 1009-2137. 
www.intechopen.com
Advances in Regenerative Medicine
Edited by Dr Sabine Wislet-Gendebien
ISBN 978-953-307-732-1
Hard cover, 404 pages
Publisher InTech
Published online 21, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Even if the origins of regenerative medicine can be found in Greek mythology, as attested by the story of
Prometheus, the Greek god whose immortal liver was feasted on day after day by Zeus' eagle; many
challenges persist in order to successfully regenerate lost cells, tissues or organs and rebuild all connections
and functions. In this book, we will cover a few aspects of regenerative medicine highlighting major advances
and remaining challenges in cellular therapy and tissue/organ engineering.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Christopher J. Centeno and Stephen J. Faulkner (2011). Regenerative Orthopedics, Advances in
Regenerative Medicine, Dr Sabine Wislet-Gendebien (Ed.), ISBN: 978-953-307-732-1, InTech, Available from:
http://www.intechopen.com/books/advances-in-regenerative-medicine/regenerative-orthopedics
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
